754 related articles for article (PubMed ID: 27088239)
1. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
[TBL] [Abstract][Full Text] [Related]
2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
3. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
[TBL] [Abstract][Full Text] [Related]
4. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
5. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
Krammer F; Palese P
J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
[TBL] [Abstract][Full Text] [Related]
6. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.
Henry C; Palm AE; Utset HA; Huang M; Ho IY; Zheng NY; Fitzgerald T; Neu KE; Chen YQ; Krammer F; Treanor JJ; Sant AJ; Topham DJ; Wilson PC
J Virol; 2019 Nov; 93(21):. PubMed ID: 31434733
[TBL] [Abstract][Full Text] [Related]
8. The influenza virus hemagglutinin head evolves faster than the stalk domain.
Kirkpatrick E; Qiu X; Wilson PC; Bahl J; Krammer F
Sci Rep; 2018 Jul; 8(1):10432. PubMed ID: 29992986
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge.
Kuenstling TE; Sambol AR; Hinrichs SH; Larson MA
Sci Rep; 2018 Aug; 8(1):11856. PubMed ID: 30087372
[TBL] [Abstract][Full Text] [Related]
10. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.
Krammer F; Hai R; Yondola M; Tan GS; Leyva-Grado VH; Ryder AB; Miller MS; Rose JK; Palese P; García-Sastre A; Albrecht RA
J Virol; 2014 Mar; 88(6):3432-42. PubMed ID: 24403585
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
[TBL] [Abstract][Full Text] [Related]
12. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.
Krammer F; Pica N; Hai R; Margine I; Palese P
J Virol; 2013 Jun; 87(12):6542-50. PubMed ID: 23576508
[TBL] [Abstract][Full Text] [Related]
13. An epitope on the stem region of hemagglutinin of H1N1 influenza A virus recognized by neutralizing monoclonal antibody.
Yan L; Wang H; Sun L; Liu Y; Sun J; Zhao X; Li Y; Xie X; Hu J
Biochem Biophys Res Commun; 2019 Oct; 518(2):319-324. PubMed ID: 31421820
[TBL] [Abstract][Full Text] [Related]
14. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
[TBL] [Abstract][Full Text] [Related]
15. A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses.
Boonsathorn N; Panthong S; Koksunan S; Chittaganpitch M; Phuygun S; Waicharoen S; Prachasupap A; Sasaki T; Kubota-Koketsu R; Yasugi M; Ono K; Arai Y; Kurosu T; Sawanpanyalert P; Ikuta K; Watanabe Y
Biochem Biophys Res Commun; 2014 Sep; 452(3):865-70. PubMed ID: 25204499
[TBL] [Abstract][Full Text] [Related]
16. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
17. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
19. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
